MAM
DNTH icon

Meeder Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Meeder Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-8
Closed -$1K – 2294
2019
Q3 		$1K Buy
8
+2
+33% +$380 ﹤0.01% 2050
2019
Q2 		$1K Hold
6
– – ﹤0.01% 1940
2019
Q1 		$1K Buy
+6
New +$1.03K ﹤0.01% 1615

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Meeder Asset Management's DNTH Position: Q4 2019 in Review

Meeder Asset Management sold out of Dianthus Therapeutics (DNTH) in Q4 2019, closing a stake of 8 shares — an estimated $1K sold.

Meeder Asset Management first reported a position in DNTH in Q1 2019 and held it in 3 quarters. The position peaked at $1K in Q3 2019. 74 funds tracked by Wall St. Rank hold DNTH as of Q4 2019.

  • Meeder Asset Management reported no remaining Dianthus Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Meeder Asset Management sold 8 Dianthus Therapeutics shares in Q4 2019, an estimated $1K.
  • Meeder Asset Management first reported a position in Dianthus Therapeutics in Q1 2019 and held it in 3 quarters.
  • Meeder Asset Management's Dianthus Therapeutics position peaked at $1K in Q3 2019.
  • 74 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2019.

Based on Meeder Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.